LATEST NEWS

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

April 9, 2024 (UK) | Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.

Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma

August 1, 2023 (Manchester, UK) | Renaissance Pharma Ltd., a rapidly emerging company focused on the development of life changing therapies in paediatric rare disease, launches today and announces the signing of an exclusive license agreement with St. Jude Children’s Research Hospital (“St. Jude”) for Hu14.18, a humanised antibody product in development by St. Jude for the first line treatment of high-risk neuroblastoma.